Evidence map›Paper›PMID 28595619›Full record

ArticleStem cell research & therapy2017

Cytokine treatment optimises the immunotherapeutic effects of umbilical cord-derived MSC for treatment of inflammatory liver disease.

Samantha F H de Witte, Ana M Merino, Marcella Franquesa, Tanja Strini, Johanna A A van Zoggel, Sander S Korevaar, Franka Luk, Madhu Gargesha, Lisa O'Flynn, Debashish Roy and 4 more

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 104 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 4 countries.

Samantha F H de WitteNephrology and Transplantation, Department of Internal Medicine, Erasmus MC, Postbus 2040, 3000 CA, Rotterdam, The Netherlands. s.dewitte@erasmusmc.nl.
Ana M MerinoNephrology and Transplantation, Department of Internal Medicine, Erasmus MC, Postbus 2040, 3000 CA, Rotterdam, The Netherlands.
Marcella FranquesaNephrology and Transplantation, Department of Internal Medicine, Erasmus MC, Postbus 2040, 3000 CA, Rotterdam, The Netherlands.
Tanja StriniNephrology and Transplantation, Department of Internal Medicine, Erasmus MC, Postbus 2040, 3000 CA, Rotterdam, The Netherlands.
Johanna A A van ZoggelExperimental Urology Department, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands.
Sander S KorevaarNephrology and Transplantation, Department of Internal Medicine, Erasmus MC, Postbus 2040, 3000 CA, Rotterdam, The Netherlands.
Franka LukNephrology and Transplantation, Department of Internal Medicine, Erasmus MC, Postbus 2040, 3000 CA, Rotterdam, The Netherlands.
Madhu GargeshaBioInVision Inc, Mayfield Village, OH, USA.
Lisa O'FlynnOrbsen Therapeutics Ltd, Galway, Ireland.
Debashish RoyBioInVision Inc, Mayfield Village, OH, USA.
Steve J EllimanOrbsen Therapeutics Ltd, Galway, Ireland.
Philip N NewsomeNational Institute for Health Research (NIHR) Birmingham Liver Biomedical Research Unit and Centre for Liver Research, University of Birmingham, Birmingham, UK.
Carla C BaanNephrology and Transplantation, Department of Internal Medicine, Erasmus MC, Postbus 2040, 3000 CA, Rotterdam, The Netherlands.
Martin J HoogduijnNephrology and Transplantation, Department of Internal Medicine, Erasmus MC, Postbus 2040, 3000 CA, Rotterdam, The Netherlands.
Erasmus University Rotterdam · NLBioInVision (United States) · USOrbsen Therapeutics (Ireland) · IEErasmus MC · NLNIHR Birmingham Liver Biomedical Research Unit · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMesenchymal stromal cells (MSC) possess immunomodulatory properties and low immunogenicity, both crucial properties for their development into an effective cellular immunotherapy. They have shown benefit in clinical trials targeting liver diseases; however the efficacy of MSC therapy will benefit from improvement of the immunomodulatory and immunogenic properties of MSC.

methodsMSC derived from human umbilical cords (ucMSC) were treated for 3 days in vitro with various inflammatory factors, interleukins, vitamins and serum deprivation. Their immunogenicity and immunomodulatory capacity were examined by gene-expression analysis, surface-marker expressions, IDO activity, PGE

resultsIFN-γ and a multiple cytokine cocktail (MC) consisting of IFN-γ, TGFβ and retinoic acid upregulated the expression of immunomodulatory factor PD-L1 and IDO activity. Subsequently, both treatments enhanced the capacity of ucMSC to inhibit CD4 and CD8 T cell proliferation and IFN-γ production. The susceptibility of ucMSC for NK cell lysis was decreased by IFN-β, TGFβ and MC treatment. In vivo, no immunomodulation was observed by the ucMSC. Four hours after intravenous infusion in mice with CCl

conclusionsThe present study demonstrates the responsiveness of ucMSC to in vitro optimisation treatment. The observed improvements in immunomodulatory capacity as well as immunogenicity after MC treatment may improve the efficacy of ucMSC as immunotherapy targeted towards liver inflammation.

Indexed as

Mesenchymal Stem Cell TransplantationAnimalsCell ProliferationCytokinesHumansInflammationInterferon-gammaKiller Cells, NaturalLiver DiseasesMesenchymal Stem CellsMiceUmbilical CordCytokinesInterferon-gammaImmunogenicImmunomodulatoryMesenchymal stromal cellOptimising

Identifiers

PMID28595619
PMCPMC5465593
OpenAlexW2621945653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.